•  | 

Acute Respiratory Distress Syndrome Market Analysis Forecast 2024-2032

Acute Respiratory Distress Syndrome Market Analysis

The Global Acute Respiratory Distress Syndrome Market is projected to reach up to USD 2.36 billion by 2032, up from US$ 1.23 billion in 2023, with a compound annual growth rate of 7.49% from 2024 to 2032.

Acute Respiratory Distress Syndrome (ARDS) is a critical condition characterized by the failure of multiple organs, with the lungs, especially the alveoli, being inundated with fluids that impede the delivery of oxygen to the body’s vital organs. ARDS often arises in conjunction with underlying conditions such as sepsis, pneumonia, or inhalation injuries caused by toxic substances. The telltale signs of ARDS include labored breathing, low blood pressure, and an elevated respiratory rate. Treatment typically involves the use of mechanical ventilation, intravenous fluids, and inhaled medications to manage the symptoms. It’s estimated that more than 3 million people worldwide develop ARDS each year due to factors such as air pollution and exposure to toxic gases. According to the World Health Organization (WHO), approximately 3 million individuals are affected by ARDS annually across the globe.


Request a free sample copy of the report: https://www.renub.com/acute-respiratory-distress-syndrome-market-p.php


Driving Factor of Acute Respiratory Distress Syndrome

Growing Air Pullulations: Rising air pollution is a pressing global issue exacerbated by industrial activities, transportation emissions, and urbanization. Particulate matter, nitrogen oxides, and volatile organic compounds contribute to smog formation and respiratory health problems. The combustion of fossil fuels in vehicles and power plants releases pollutants that degrade air quality and harm ecosystems. Efforts to mitigate air pollution include stricter emission regulations, technological advancements in clean energy, and public awareness campaigns. Addressing air pollution requires coordinated efforts across sectors to reduce greenhouse gas emissions and promote sustainable practices. Improving air quality not only protects human health but also supports environmental sustainability and mitigates the impacts of climate change.


The effect of Acute Respiratory Distress Syndrome on healthcare systems globally: The impact of Acute Respiratory Distress Syndrome on healthcare systems worldwide is significant. It leads to increased admissions to critical care units and hospitals. Statistics from countries such as Australia, France, and the U.S. demonstrate this trend. It is crucial to increase investment in healthcare for Acute Respiratory Distress Syndrome to improve patient outcomes and reduce the burden of potentially fatal conditions. This requires intensive medical intervention and advanced medical technologies. It is anticipated that global healthcare infrastructure investment will experience significant growth by 2025, particularly in the Middle East, Africa, and Asia.


United States Acute Respiratory Distress Syndrome Market

The market for acute respiratory distress syndrome (ARDS) in the USA is experiencing significant growth, primarily due to the rising incidence of acute lung injury. Factors contributing to this trend include the expanding patient pool affected by ARDS. Many companies in the United States have redirected their attention to this particular therapeutic area in order to address the unmet demand for ARDS treatments. The development of emerging therapies specifically targeting ARDS is expected to have a substantial impact on the market size. According to the World Health Organization (WHO), an estimated 200,000 individuals in the United States are afflicted by ARDS annually. Chronic respiratory conditions such as asthma play a major role in causing ARDS, with over 34 million individuals in the U.S. grappling with chronic lung diseases like asthma and chronic obstructive pulmonary disease (COPD).


Global Acute Respiratory Distress Syndrome Company Analysis

Prominent players in the Acute Respiratory Distress Syndrome Market are Silence Therapeutics plc, Gilead Sciences Inc., Terumo Corporation, Getinge AB, Livanova Plc, Medtronic, Inc., Fresenius Se & Co. KGAA, Nipro, and Pfizer Inc.


Acute Respiratory Distress Syndrome Company New

Jan 2024: LivaNova PLC is winding down its ACS Business Unit to focus on its core Cardiopulmonary and Neuromodulation Business Units. The wind-down process is expected to be completed by the end of 2024.

Feb 2024: Silence Therapeutics received a $10 million milestone payment from AstraZeneca to begin a phase 1 clinical trial for their siRNA collaboration.

March 2024: Gilead Sciences, Inc. and Xilio Therapeutics, Inc. announced exclusive license agreements for Xilio’s tumor-activated IL-12 program, XTX301.

March 2024: Terumo Blood and Cell Technologies partnered with the CiRA Foundation to develop automated iPS cell manufacturing.

March 2024: Getinge has announced the U.S. launch of the Corin Operating Table and Ezea Surgical Light at AORN.

March 2024: The FDA has approved Medtronic’s Evolut FX+ TAVR system for treating severe aortic stenosis. This system retains the benefits of the earlier Evolut TAVR platform and allows easier coronary access.

April 2024, Pfizer Inc. has reported successful results from Phase 3 clinical trials for ABRYSVO, a single-dose vaccine designed for adults aged 18 to 59 at risk of severe RSV-associated LRTD.

In December 2022, Terumo Corp. and Kyowa Kirin Co. launched “G-Lasta Subcutaneous Injection 3.6 mg BodyPod” in Japan.


Type – Market is divided into 2 viewpoints

  1. Diagnosis
  2. Treatment


End User – Market is divided into 4 viewpoints

  1. Hospitals
  2. Specialty clinics
  3. Home healthcare
  4. Others


Countries – Market is divided into 25 Country Acute Respiratory Distress Syndrome Industry

North America

  1. United States
  2. Canada


  1. France
  2. Germany
  3. Italy
  4. Spain
  5. United Kingdom
  6. Belgium
  7. Netherlands
  8. Turkey


Asia Pacific

  1. China
  2. Japan
  3. India
  4. Australia
  5. South Korea
  6. Thailand
  7. Malaysia
  8. Indonesia
  9. New Zealand


Latin America

  1. Brazil
  2. Mexico
  3. Argentina


Middle East & Africa

  1. South Africa
  2. Saudi Arabia
  3. United Arab Emirates


Key Players: All key players have been covered from 4 points


  1. Overviews
  2. Recent Developments
  3. Product Portfolio
  4. Revenue


Company Analysis:


  1. Silence Therapeutics plc
  2. Gilead Seiences Inc.
  3. Terumo Corporation
  4. Getinge AB
  5. Livanova Plc
  6. Medtronic, Inc.
  7. Fresenius Se & Co. KGAA
  8. Nipro
  9. Pfizer Inc.



About the Company:

Renub Research is a Market Research and Information Analysis company with more than 15 years of experience in Research, Survey, and Consulting. Our research helps companies to take business decisions: on strategy, organization, operations, technology, mergers & acquisitions, etc. Till now we have published more than 9000 syndicated reports and worked on more than 750 custom research projects. Currently, we are supplying data to EMIS, Bloomberg, Thomson Reuters, etc. We support many blue-chip companies by providing them with findings and perspectives across a wide range of markets.


Contact Us:

Renub Research

Phone No: +1-478-202-3244 | +91-120-421-9822 (IND)

Email: info@renub.com

LinkedIn: https://in.linkedin.com/company/renub-research

Website: https://www.renub.com/

Secured By miniOrange